

### **REMARKS**

Claims 1-30 are pending. Claims 1, 2, 4-6, 8, 9, 11, 12 and 19-30 are rejected. Objected to are claims 3, 7, 10 and 13-18. Claims 1, 10, 11, 18, 19, 27, and 30 have been amended. Claims 2 and 12 have been cancelled. No new matter has been added. Importantly, any claim amendments and/or cancellations made herein should not be construed to be an acquiescence to any of the claim rejections. Rather, these actions are being made solely to expedite the prosecution of the above-identified application. The Applicants expressly reserve the right to further prosecute the same or similar claims in subsequent patent applications claiming the benefit of priority to the instant application (35 USC § 120).

### **CLAIM OBJECTIONS**

The Examiner has objected to claims 10, 18, and 30 for being illegible. In addition, claim 30 has been objected to because it does not end with a period. Claims 10, 18, and 30 have been amended to address the Examiner's objections. Specifically, new compound structures have been provided and a period has been added to the end of claim 30. Therefore, the Applicants respectfully request the Examiner withdraw his objections to claims 10, 18, and 30.

### **SPECIFICATION**

The Examiner has objected to the disclosure because it contains figures/drawings incorporated within the text as opposed to on separate drawing sheets. In addition, the Examiner has noted that a brief description of the figures should be provided.

Submitted herewith are thirty four (34) sheets of drawings consisting of Figures 1-27B. Figures 1-27B correspond to the illustrations originally in the Specification, which have been deleted; therefore, no new matter has been added. In addition, the Specification has been amended to include a brief description of the figures based on the illustration captions originally in the Specification, which have been deleted; therefore, no new matter has been added. Finally, appropriate conforming amendments (and spelling corrections) have been made to the specification, replacing references to the removed illustrations with references to Figures 1-27B; no new matter has been added. Based on the amendments just described, the Applicants believe


they have made the appropriate corrections and respectfully request the Examiner withdraw his objection to the Specification.

### **CLAIM REJECTIONS BASED ON 35 USC § 112¶2**

Claims 19-30 are rejected as being indefinite for failing to particularly point out and distinctly claim the subject matter which the Applicant regards as the invention. Independent claims 19 and 27 are explicitly rejected, while claims 20-26 and 28-30 are rejected for depending on rejected independent claims 19 and 27.

In particular, the Examiner asserts that independent claim 19 is indefinite because compound **V** does not represent a “glycosylphatidylinositol glycan” In addition, the Examiner further asserts that claim 19 is indefinite “because it is unclear what specific reactants are used and how they are used in said process because no method steps are recited in the claim.” Lastly, the Examiner asserts that independent claim 27 is indefinite because it “fails to recite when or where in the process is the said glycosylphatidylinositol glycan produced.” The Applicants respectfully traverse.

To expedite prosecution of the application, the Applicants have amended claim 19 to replace the preamble which contained “preparing glycosylphosphatidylinositol glycans” and Scheme 5 with: “A method comprising the step of combining a compound represented by



Support for this amendment can be found throughout the application, including in Scheme 5. This amendment does not change the scope of the pending claims. Importantly, the Applicants believe the amended claim clearly indicates the specific reactants to be combined and the product produced therefrom.

Claim 27 has also been amended to replace “glycosylphosphatidylinositol glycans” with “tetrasaccharide”. Support for this amendment can be found throughout the application, including the final line of claim 27, which recites that a tetrasaccharide is cleaved from a solid support. This amendment does not change the scope of the pending claims. Importantly, the amended claim clearly indicates in the preamble what type of compound is produced by the claimed method.

Based on the amendments just described, the Applicants respectfully request the Examiner withdraw his rejections of claims 19-30 based on 35 USC § 112¶2.

#### **CLAIM REJECTIONS BASED ON 35 USC § 112¶1**

The Examiner has rejected independent claim 19, as well as dependent claims 20-26, for containing subject matter which was not described in the Specification in such a way as to reasonably convey to one of skill in the relevant art the inventor(s), at the time the application was filed, had possession of the claimed invention. The Applicants respectfully traverse.

Claim 19 has been amended to replace Scheme 5 with a description of the specific step it represents, namely the combination of two compounds with N-iodosuccinimide and silver triflate. In addition, the experimental procedure provided on page 36 (bottom; for compound **20**) is one wherein compound of the type described in Scheme 5 are combined with silver triflate (AgOTf) and N-iodosuccinimide (NIS). Based on Scheme 5, the disclosed synthesis of compound **20**, as well as the rest of the disclosure, the Applicants respectfully assert that the application does convey to one of skill in the art (namely, a organic chemist with a PhD in that field) that the inventors had possession of the claimed invention. Therefore, the Applicants respectfully request that the Examiner withdraw his rejections of claims 19-26 based on 35 USC § 112¶1.

#### **CLAIM REJECTIONS BASED ON 35 USC § 102(b)**

The Examiner has rejected claims 1, 2, 4, 8, and 9 as being anticipated by Madsen *et al.* (*J. Am. Chem. Soc.* **1995**, *117*(5), 1554-1565). Specifically, the Examiner asserts that Madsen on

page 1563 (compound **30**) teaches a compound which falls within the scope of formula **I** wherein n is 2, R is H, R<sup>1</sup> is H, R<sup>2</sup> is H, R<sup>3</sup> is amino, and R<sup>4</sup> is H.

In addition, the Examiner has rejected claims 1, 2, 6, 8, and 9 as being anticipated by Martin-Lomas *et al.* (*Chem. Eur. J.* **2000**, 6(19), 3608-3612). Specifically, the Examiner asserts that Martin-Lomas on page 3610 (compound **3**) teaches a compound which falls within the scope of formula **I** wherein n is 2, R is -CH<sub>2</sub>aryl (benzyl), R<sup>1</sup> is H, R<sup>2</sup> is H, R<sup>3</sup> is N<sub>3</sub>, and R<sup>4</sup> is -CH<sub>2</sub>aryl (benzyl).

Further, the Examiner has rejected claims 1, 2, 6, 8, and 9 as being anticipated by Jaworek *et al.* (*Carbohydrate Res.* **2001**, 331, 375-391). Specifically, the Examiner asserts that Jaworek teaches on page 376 (compound **5**) a compound which falls within the scope of formula **I** wherein n is 2, R is H, R<sup>1</sup> and R<sup>2</sup> taken together are P(O)OH, R<sup>3</sup> is amino, and R<sup>4</sup> is -CH<sub>2</sub>aryl (benzyl).

Lastly, the Examiner has rejected claims 11 and 12 as being anticipated by Rademacher *et al.* (WO 01/85745 A1). Specifically, the Examiner asserts that Rademacher teaches in Scheme 5(I) (compound **20**) a compound which falls within the scope of formula **II** wherein n is 2, R is -CH<sub>2</sub>aryl (benzyl), and R<sup>1</sup> is C(=NH)CCl<sub>3</sub>.

Solely to expedite the prosecution of this application, the Applicants have amended independent claims 1 and 11 to limit n to 1, 3 or 4. In addition, claims 2 and 12 have been canceled. The compounds cited by the Examiner do not fall within the scope of the amended claims. Therefore, the Applicants respectfully request the Examiner withdraw his rejections of claim 1, 2, 4, 8, 9, 11 and 12 under 35 USC § 102(b) based on Madsen, Martin-Lomas, Jaworek or Rademacher.

### **ALLOWABLE SUBJECT MATTER**

The Applicants note with appreciation that the Examiner has indicating that claims 3, 7, 10, 13-18 would be allowable if rewritten in independent form including all the limitations of the base claim and any intervening claims. Claim 10 has been rewritten as an independent claim.

### **FEES**

The Applicants believe they have provided for all required fees in connection with the filing of this paper. Nevertheless, the Director is hereby authorized to charge any additional required fee to our Deposit Account, **06-1448**, Reference **MTV-055.01**.

### **CONCLUSION**

In view of the above remarks, it is believed that the pending claims are in condition for allowance. The Applicants respectfully request reconsideration and withdrawal of the pending rejections. The Applicants thank the Examiner for careful consideration of the present case. If a telephone conversation with the Applicants' Agent would expedite prosecution of the above-identified application, the Examiner is urged to contact the undersigned.

Patent Group  
FOLEY HOAG LLP  
155 Seaport Boulevard  
Boston, MA 02210  
617-832-1000  
617-832-7000 (FAX)

Respectfully submitted,  
FOLEY HOAG LLP

/Jacob I. Wasserman/  
Jacob I. Wasserman, Ph.D.  
Agent for Applicants  
Registration No. 56,929

Date: June 15, 2007